BXT-25 is predicted to oxygenate the mind and be monitored by Bioxytran’s FDA accredited medical machine to hint all oxygen molecules
BOSTON, MASSACHUSETTS, July 8, 2024 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a scientific stage biotechnology firm growing medicine to deal with stroke and Alzheimer’s illness, introduced that Bioxtran’s Science Advisor Prof. Avraham Mayevsky’s ebook titled Hyperbaric Oxygenation Mitochondrial Exercise and Mind Physiological Features was revealed by a publishing home, Springer. It’s out there by eBook or Hardcover. The ebook is instantly tied to the Hypoxia platform expertise which makes use of the MDX Viewer as an analytical technique, which is an FDA accredited machine to measure tissue oxygenation. The machine measures the consumption of oxygen molecules in tissues on a mobile degree. The output of the MDX Viewer is the Mind Metabolic Rating BMS, which is a crucial a part of the approval course of for Bioxytran’s acellular oxygen service (AOC) molecule referred to as BXT-25. Bioxytran plans on utilizing the BXT-25 in its scientific trials for ischemic stroke and Alzheimer’s illness sufferers as a technique to change hyperbaric oxygen therapy (HBOT).
https://hyperlink.springer.com/ebook/10.1007/978-3-031-49681-3
The ebook is a complete overview of the results of hyperbaric oxygen on mind capabilities together with mitochondrial exercise. The MDX viewer is an FDA accredited medical machine that measures tissue metabolic rating and its outcomes are cited many instances all through the ebook. The outcomes from the MDX viewer supplied a stable basis upon which he was capable of additional elucidate the connection between oxygenation and cerebral perform with respect to hyperbaric oxygenation therapy. The ebook additionally discusses the results of hyperbaric oxygen therapy on mind biochemical and physiological responses that may affect mitochondrial exercise, which is important for vitality manufacturing. The proof means that hyperbaric oxygen improves cerebral blood circulation and tissue oxygenation which in the end ends in a optimistic impression on mind functioning and efficiency.
“BXT-25 is expected to oxygenate the brain and other human organs and tissues,” stated Avraham Mayevsky, Member of Bioxytran’s Medical Advisory Board. “One of the biggest challenges in in clinical trials is determining the efficacy of a drug. One of the most widely held beliefs in medicine is that increased mitochondrial activity at the cellular level means cells are working more efficiently and that ultimately leads to a demonstration of efficacy of a drug. The MDX viewer is an FDA approved device that monitors oxygenation in real time and is so sensitive, that it’s conceivable future applications could be used as an endpoint of efficacy. Drugs capable of treating diseases will ultimately impact they body by increasing the BMS. This means that if a patient baseline BMS is established and then an efficacious drug is introduced the BMS will rise. Conversely if a drug is tested on a person who experiences side effects, its likely the BMS will go down. Since BXT-25 is essentially a miniaturized oxygen carrier we would expect to see favorable increases in BMS. Coupling the MDX Viewer in clinical trials with drugs like BXT-25 could significantly shorten the clinical trial processes an demonstrate efficacy on a cellular level using an unbiased biomarker instead of surrogate biomarkers to demonstrate efficacy. Ultimately, I see this will shorten the time for FDA approval as a universal oxygen carrier for tissue oxygenation.”
About Bioxytran, Inc.
Bioxytran, Inc. is a scientific stage biotechnology firm growing a drug to deal with stroke in an early stage and Alzheimer’s illness by delivering oxygen with a molecule that’s 5000 instances smaller than a purple blood cell. Extra data will be discovered at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Ahead-Wanting Statements
This press release contains forward-looking statements as outlined underneath federal regulation, together with these associated to the efficiency of expertise described on this press release. These forward-looking statements are usually recognized by the phrases “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and comparable expressions, though not all forward-looking statements include these figuring out phrases. Such statements are topic to important dangers, assumptions and uncertainties. Recognized materials components that might trigger Bioxytran’s precise outcomes to vary materially from the outcomes contemplated by such forward-looking statements are described within the forward-looking statements and danger components within the Firm’s Annual Report on Type 10-Okay for the fiscal 12 months ended December 31, 2023 and people danger components set forth from time-to-time in different filings with the Securities and Trade Fee. Bioxytran undertakes no obligation to appropriate or replace any forward-looking assertion, whether or not on account of new data, future occasions, or in any other case, besides to the extent required underneath federal securities legal guidelines.
Media Contact:
david.platt@bioxytraninc.com
6175102539
www.bioxytrantinc.com
Bioxytran
David Platt